Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
- Product: Rebif
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Rebif 22microg/0.5ml (6million units) inj pre-filled pens
0802040M0BBAJAM
|
Rebif | Interferon beta | Malignant Disease and Immunosuppression | No data available |
|
Rebif 22microg/0.5ml inj and Rebif 8.8microg/0.2ml inj
0802040M0BBALAQ
|
Rebif | Interferon beta | Malignant Disease and Immunosuppression | No data available |
|
Rebif 22microg/0.5ml inj and Rebif 8.8microg/0.2ml inj pfs
0802040M0BBAFAI
|
Rebif | Interferon beta | Malignant Disease and Immunosuppression | No data available |
|
Rebif 22micrograms/0.5ml (6million units) inj 1.5ml cart
0802040M0BBAGAJ
|
Rebif | Interferon beta | Malignant Disease and Immunosuppression | No data available |
|
Rebif 22micrograms/0.5ml (6million units) inj pfs
0802040M0BBADAF
|
Rebif | Interferon beta | Malignant Disease and Immunosuppression | No data available |
|
Rebif 44micrograms/0.5ml (12million units) inj 1.5ml cart
0802040M0BBAHAK
|
Rebif | Interferon beta | Malignant Disease and Immunosuppression | No data available |
|
Rebif 44micrograms/0.5ml (12million units) inj pf pens
0802040M0BBAKAN
|
Rebif | Interferon beta | Malignant Disease and Immunosuppression | No data available |
|
Rebif 44micrograms/0.5ml (12million units) inj pfs
0802040M0BBAEAG
|
Rebif | Interferon beta | Malignant Disease and Immunosuppression | No data available |
|
Rebif 8.8microg/0.1ml with 22microg/0.25ml initiation pack
0802040M0BBAIAL
|
Rebif | Interferon beta | Malignant Disease and Immunosuppression | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.